Tcr2 Therapeutics Inc (TCRR) Director Purchases $10,000,005.00 in Stock

Tcr2 Therapeutics Inc (NASDAQ:TCRR) Director Morana Jovan-Embiricos acquired 666,667 shares of the business’s stock in a transaction on Tuesday, February 19th. The shares were purchased at an average price of $15.00 per share, with a total value of $10,000,005.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

NASDAQ:TCRR opened at $16.03 on Friday. Tcr2 Therapeutics Inc has a 12 month low of $14.80 and a 12 month high of $16.57.

WARNING: This article was posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://dakotafinancialnews.com/2019/02/23/tcr2-therapeutics-inc-tcrr-director-purchases-10000005-00-in-stock.html.

Tcr2 Therapeutics Company Profile



TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

See Also: Channel Trading

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.